-
Necrostatin-1: RIP1 Kinase Inhibitor Workflows
2026-08-20
Build more discriminating necroptosis assays with Necrostatin-1, a selective RIP1 kinase inhibitor that connects cell-death signaling to inflammatory tissue injury. This guide translates evidence from cough variant asthma research into practical workflows, controls, and troubleshooting strategies for cell, lung, liver, and acute kidney injury models.
-
Remdesivir: Polymerase Biology for Better Assays
2026-08-20
Remdesivir (GS-5734) is examined through a polymerase-centered lens, connecting coronavirus and filovirus data with new structural insights into Nipah virus replication machinery. The article translates those findings into better assay design, interpretation, and compound-handling decisions.
-
Gentamycin Sulfate in Resistance Research
2026-08-19
Gentamycin Sulfate is an aminoglycoside antibiotic that connects ribosome-level perturbation with modern bacterial resistance research. This article explains how to use it as a mechanistic assay tool while interpreting insights from a major European study of resistant Gram-negative pathogens.
-
Adefovir Workflows for HBV and OAT1 Research
2026-08-19
A practical guide to using Adefovir (GS-0393) in HBV polymerase assays, resistance studies, and OAT1 transporter phenotyping. The workflow emphasizes aqueous formulation, clinically informed concentration selection, mechanistic controls, and troubleshooting for reproducible data.
-
Aurora Kinase A in Retinoblastoma: Study Insights
2026-08-18
A 2024 study links elevated Aurora kinase A (AURKA) expression in retinoblastoma to histopathologic high-risk features and poor chemotherapy response. By combining patient-tissue analysis with genetic and pharmacologic perturbation across cellular, xenograft, and enucleated-tumor models, the work provides a preclinical rationale for testing selective Aurora A inhibition in high-risk disease.
-
Necrostatin-1 for RIP1 Kinase Necroptosis Assays
2026-08-18
Necrostatin-1 is a selective RIP1 kinase inhibitor for resolving TNF-α-driven necroptosis in cell and tissue-injury models. This guide translates its mechanism into practical workflows, pathway controls, ferroptosis-aware assay design, and troubleshooting strategies.
-
Harpagoside Targets EGFR-TKI Resistance in Lung Cancer
2026-08-17
The reference study links acquired gefitinib resistance in EGFR-mutant lung adenocarcinoma cells to stemness-associated and inflammatory gene changes, EMT-like features, and enhanced tumor behavior. It further shows that harpagoside can enhance gefitinib or paclitaxel responses, with the paclitaxel combination engaging apoptosis and ferroptosis through suppression of Nrf2 signaling.
-
Harpagoside Targets Resistance in EGFR-Mutant NSCLC
2026-08-17
This 2025 Journal of Functional Foods study shows that harpagoside can improve gefitinib and paclitaxel responses in EGFR-mutant lung adenocarcinoma models. Its main mechanistic contribution is linking combination treatment to suppression of Nrf2-associated defenses, with concurrent induction of apoptosis and ferroptosis and reduced metastatic behavior.
-
TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas
2026-08-16
The reference study identifies TRIM21 as a regulator of ERK1/2 ubiquitination, phosphorylation, proliferation, and dopamine-agonist resistance in pituitary adenomas. Its combination of CRISPR screening, biochemical validation, resistance models, and NanoBiT-based compound screening positions TRIM21 as a mechanistically supported—but still preclinical—therapeutic target.
-
Morin: Podocyte Energy Assay Workflow
2026-08-15
Morin combines pathway-focused podocyte research with practical fluorescence applications, offering a way to study mitochondrial energy imbalance, AMPD activity, and aluminum-ion detection in parallel. This workflow translates recent fructose-injury findings into reproducible cell, biochemical, and optimization strategies.
-
S63845 MCL1 Inhibitor: Assay Design Guide
2026-08-14
A scenario-based guide to using S63845 MCL1 inhibitor (SKU A8737) in viability, proliferation, and mitochondrial apoptosis assays. It covers mechanism, controls, dosing, solvent handling, interpretation, and practical criteria for selecting a dependable research reagent.
-
USP7–PKM2 Axis in Severe Acute Pancreatitis
2026-08-14
A 2025 Cell Death and Disease study identifies USP7 as an upstream regulator of PKM2-dependent metabolic reprogramming in macrophages during severe acute pancreatitis. Genetic and pharmacological experiments link USP7-mediated PKM2 deubiquitination to M1 polarization, inflammatory injury, and a potentially actionable immunometabolic pathway.
-
Estradiol Workflows for ER Signaling and Autophagy
2026-08-13
Build receptor-aware cell assays, autophagy readouts, and multi-organ validation workflows around 17 beta-estradiol. This guide translates recent cohort, network, and mouse evidence into practical dose design, controls, troubleshooting, and translational assay choices.
-
FBXO22 Ligands Expand Targeted Protein Degradation
2026-08-13
This 2025 bioRxiv preprint develops chemical probes that selectively degrade FBXO22 and introduces 2-pyridinecarboxaldehyde as a recruitment ligand for FBXO22-based targeted protein degradation. The findings provide a route beyond commonly used CRBN and VHL recruiters, while identifying structural and mechanistic parameters that influence FBXO22 activity.
-
HMGB1 as an Early Serum Biomarker for Diabetic Nephropathy
2026-08-12
Peng et al. used quantitative serum proteomics, Mfuzz clustering, and weighted gene co-expression network analysis to identify HMGB1 as a promising candidate for monitoring diabetic nephropathy progression. Validation in high-glucose cell and animal models supports biological relevance, but independent clinical validation and standardized assay thresholds remain necessary before diagnostic implementation.